Bioatla Inc (BCAB) - Stock Price & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09077B1044
BioAtla, Inc. is a clinical stage biopharmaceutical company that focuses on developing antibody-based therapeutics for solid tumor cancer treatment. The company's flagship product, BA3011, is a novel CAB antibody-drug conjugate designed for soft tissue and bone sarcoma tumors, NSCLC, and ovarian cancer.
In addition to BA3011, BioAtla, Inc. is actively working on other innovative products like BA3021, a CAB ADC intended for various solid tumor types such as NSCLC, melanoma, and head and neck cancer. Furthermore, the company is also researching BA3071, a CAB anti-CTLA4 antibody targeting cancers like renal cell carcinoma, small cell lung cancer, and melanoma, among others.
Founded in 2007 and headquartered in San Diego, California, BioAtla, Inc. is committed to advancing the field of cancer therapy through cutting-edge biopharmaceutical research and development. To learn more about their work, visit their website at https://www.bioatla.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
BCAB Stock Overview
| Market Cap in USD | 181m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC SubIndustry | Biotechnology |
| TER | 0.00% |
| IPO / Inception | 2020-12-16 |
BCAB Stock Ratings
| Growth 5y | -5.19 |
| Fundamental | -90.0 |
| Dividend | - |
| Rel. Performance vs Sector | -4.03 |
| Analysts | 4.40/5 |
| Fair Price Momentum | 2.30 USD |
| Fair Price DCF | - |
BCAB Dividends
| Yield 12m | 0.00% |
| Yield on Cost 5y | 0.00% |
| Dividends CAGR 5y | 0.00% |
| Payout Consistency | 0.0% |
BCAB Growth Ratios
| Growth 12m | -24.63% |
| Growth Correlation 12m | -25% |
| Growth Correlation 3m | 18% |
| CAGR 5y | -52.45% |
| Sharpe Ratio 12m | -0.28 |
| Alpha vs SP500 12m | -74.16 |
| Beta vs SP500 5y weekly | 2.36 |
| ValueRay RSI | 32.81 |
| Volatility GJR Garch 1y | 120.17% |
| Price / SMA 50 | -8.3% |
| Price / SMA 200 | 10.43% |
| Current Volume | 295.3k |
| Average Volume 20d | 672.6k |
External Links for BCAB Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of April 27, 2024, the stock is trading at USD 2.54 with a total of 295,270 shares traded.
Over the past week, the price has changed by +20.67%, over one month by -15.61%, over three months by +23.30% and over the past year by -24.85%.
According to ValueRays Forecast Model, BCAB Bioatla Inc will be worth about 2.7 in April 2025. The stock is currently trading at 2.54. This means that the stock has a potential upside of +4.33%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 11.5 | 353 |
| Analysts Target Price | 14 | 451 |
| ValueRay Target Price | 2.7 | 4.33 |